REG - Haleon PLC GSK PLC - Holding(s) in Company

GSKAnnouncement

26/07/2022 17:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220726:nRSZ8244Ta&default-theme=true

RNS Number : 8244T  Haleon PLC  26 July 2022

26 July 2022

 

Haleon plc

TR-1: Standard form for notification of major holdings

 

 NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the
 FCA in Microsoft Word format if possible)

 1a. Identity of the issuer or the underlying issuer of existing shares to                                                                                    Haleon plc
 which voting rights are attached:
 1b. Please indicate if the issuer is a non-UK issuer  (please mark with an
 "X" if appropriate)
 Non-UK issuer
 2. Reason for the notification (please mark the appropriate box or boxes with
 an "X")
 An acquisition or disposal of voting rights                                                                                                                                                                                                            X
 An acquisition or disposal of financial instruments
 An event changing the breakdown of voting rights
 Other (please specify):
 3. Details of person subject to the notification obligation
 Name                                                                                                                                                         GSK plc
 City and country of registered office (if applicable)                                                                                                        London, England
 4. Full name of shareholder(s) (if different from 3.)
 Name                                                                                                                                                         Vidacos Nominees Limited
 City and country of registered office (if applicable)                                                                                                        London, England
 5. Date on which the threshold was crossed or reached :                                                                                                      25 July 2022
 6. Date on which issuer notified (DD/MM/YYYY):                                                                                                               25/07/2022
 7. Total positions of person(s) subject to the notification obligation
                                                                            % of voting rights attached to shares (total of 8. A)  % of voting rights through financial instruments      Total of both in % (8.A + 8.B)  Total number of voting rights held in issuer (8.A + 8.B)

(total of 8.B 1 + 8.B 2)
 Resulting situation on the date on which threshold was crossed or reached  12.94                                                  0                                                     12.94                           1,195,320,110
 Position of previous notification (if applicable)                          12.94                                                  0                                                     12.94

 

 8. Notified details of the resulting situation on the date on which the
 threshold was crossed or reached
 A: Voting rights attached to shares
 Class/type of                                  Number of voting rights                                                 % of voting rights

shares

 ISIN code (if possible)
                                                Direct                  Indirect                                        Direct                                           Indirect

                                                (DTR5.1)                 (DTR5.2.1)                                     (DTR5.1)                                         (DTR5.2.1)
 GB00BMX86B70                                   0                       1,195,320,110                                   0                                                12.94

 SUBTOTAL 8. A                                  1,195,320,110                                                           12.94

 B 1: Financial Instruments according to DTR5.3.1R (1) (a)
 Type of financial instrument                   Expiration  Exercise/                           Number of voting rights that may be acquired if the instrument is        % of voting rights

date
Conversion Period                  exercised/converted.

                                                            SUBTOTAL 8. B 1

 B 2: Financial Instruments with similar economic effect according to DTR5.3.1R
 (1) (b)
 Type of financial instrument  Expiration                   Exercise/               Physical or cash Settlement                                 Number of voting rights  % of voting rights

date
Conversion Period

                                                                                    SUBTOTAL 8.B.2

 

 9. Information in relation to the person subject to the notification
 obligation (please mark the

 applicable box with an "X")
 Person subject to the notification obligation is not controlled by any natural
 person or legal entity and does not control any other undertaking(s) holding
 directly or indirectly an interest in the (underlying) issuer (xiii)
 Full chain of controlled undertakings through which the voting rights and/or                                                                                                                                                                     X
 the

financial instruments are effectively held starting with the ultimate
 controlling natural person or legal entity (please add additional rows as
 necessary)
 Name                                                % of voting rights if it equals or is higher than the notifiable threshold  % of voting rights through financial instruments if it equals or is higher  Total of both if it equals or is higher than the notifiable threshold
                                                                                                                                 than the notifiable threshold
 GSK plc (Chain 1)                                   5.44                                                                                                                                                    5.44
 GlaxoSmithKline Holdings Limited (Chain 1)          5.44                                                                                                                                                    5.44
 GlaxoSmithKline Finance plc (Chain 1)               5.44                                                                                                                                                    5.44
 Glaxo Group Limited (Chain 1)                       5.44                                                                                                                                                    5.44

 GSK plc (Chain 2)                                   4.74                                                                                                                                                    4.74
 GSK LP Limited (Chain 2)                            4.74                                                                                                                                                    4.74
 GSK GP 1 Limited (Chain 2)                          4.74                                                                                                                                                    4.74
 GSK (No. 1) Scottish Limited Partnership (Chain 2)  4.74                                                                                                                                                    4.74

 GSK plc (Chain 3)                                   1.78                                                                                                                                                    1.78
 GSK LP Limited (Chain 3)                            1.78                                                                                                                                                    1.78
 GSK GP 1 Limited (Chain 3)                          1.78                                                                                                                                                    1.78
 GSK (No. 2) Scottish Limited Partnership (Chain 3)  1.78                                                                                                                                                    1.78

 GSK plc (Chain 4)                                   0.98                                                                                                                                                    0.98
 GSK LP Limited (Chain 4)                            0.98                                                                                                                                                    0.98
 GSK GP 2 Limited (Chain 4)                          0.98                                                                                                                                                    0.98
 GSK (No. 3) Scottish Limited Partnership (Chain 4)  0.98                                                                                                                                                    0.98

 10. In case of proxy voting, please identify:
 Name of the proxy holder
 The number and % of voting rights held
 The date until which the voting rights will be held

 11. Additional information
 This notification relates to the transfer by GSK plc of its direct retained
 5.44% stake in Haleon plc to Glaxo Group Limited (a wholly owned subsidiary of
 GSK plc and the holder of other external minority

 interests of the GSK group).

 The GSK group's aggregate interest in Haleon plc remains unchanged following
 the transfer.  A separate TR-1 has also been submitted today by GSK plc on
 behalf of Glaxo Group Limited and Glaxo Group Limited's parent undertakings
 (other than GSK plc) to satisfy their notification obligations.

 Glaxo Group Limited, GSK (No. 1) Scottish Limited Partnership, GSK (No. 2)
 Scottish Limited Partnership and GSK (No. 3) Scottish Limited Partnership hold
 their shares in Haleon plc via a custodian, Vidacos Nominees Limited, which
 holds the legal title to those shares on their behalf pursuant to a custody

 arrangement.

 These calculations are based on an issued share capital of Haleon plc of
 9,234,573,831 ordinary shares.

 

 Place of completion  London, England
 Date of completion   25 July 2022

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  HOLUNUNRUAUBUAR